| 0 (0%) | 04-29 13:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.62  |
1-year : | 59.5 |
| Resists | First : | 49.33 |
Second : | 50.95 |
| Pivot price | 49.29 |
|||
| Supports | First : | 46.72 |
Second : | 38.87 |
| MAs | MA(5) : | 47.85 |
MA(20) : | 49.55 |
| MA(100) : | 47.64  |
MA(250) : | 42.6 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 0 |
D(3) : | 2.8 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 50.95 | Low : | 35.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DRUP ] has closed below the lower bollinger band by 6.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 55.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 48.06 - 48.33 | 48.33 - 48.63 |
| Low: | 46.79 - 47.09 | 47.09 - 47.43 |
| Close: | 46.99 - 47.52 | 47.52 - 48.09 |
Sat, 02 Dec 2023
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine ... - ScienceDirect.com
Mon, 30 Jan 2023
Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond - ScienceDirect.com
Thu, 16 Dec 2021
Impact of cancer metabolism on therapy resistance – Clinical implications - ScienceDirect.com
Fri, 26 Nov 2021
Dutch-Nordic Alliance for Precision Cancer Medicine launched - Radboudumc
Mon, 02 Aug 2021
Korphu Drup: Success through collaboration. | World Scouting - World Scouting |
Thu, 14 Jan 2021
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance - ScienceDirect.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|